Global Radioligand Therapy Drugs for Cancer market size is predicted to grow from US$ 3203 million in 2025 to US$ 5447 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032.

Global Radioligand Therapy Drugs for Cancer Market Trends, Growth | CAGR Of 8%

The global Radioligand Therapy Drugs for Cancer market size is predicted to grow from US$ 3203 million in 2025 to US$ 5447 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032. In 2025, global Radioligand Therapy Drugs for Cancer reached approximately 76.86 K Units, with an average global market price of around 42598 USD per Unit. Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking ?ligand? (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue. Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active?including small or disseminated lesions?while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements?and in some settings competes with?established systemic therapies, shaping a long runway for growth without relying on hype. Radioligand Therapy Drugs for Cancer upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer. The production capacity of a single Radioligand Therapy Drugs for Cancer production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs for Cancer gross profit margin ranges from 70% to 80%. United States market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key Radioligand Therapy Drugs for Cancer players cover Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. Infinity Market Research newest research report, the ?Radioligand Therapy Drugs for Cancer Industry Forecast? looks at past sales and reviews total world Radioligand Therapy Drugs for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Radioligand Therapy Drugs for Cancer sales for 2026 through 2032. With Radioligand Therapy Drugs for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioligand Therapy Drugs for Cancer industry. This Insight Report provides a comprehensive analysis of the global Radioligand Therapy Drugs for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radioligand Therapy Drugs for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Radioligand Therapy Drugs for Cancer market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioligand Therapy Drugs for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioligand Therapy Drugs for Cancer. This report presents a comprehensive overview, market shares, and growth opportunities of Radioligand Therapy Drugs for Cancer market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Lutetium 177 &nbsp;&nbsp;&nbsp; Radium 223 &nbsp;&nbsp;&nbsp; Acetium 225 &nbsp;&nbsp;&nbsp; Others &nbsp;&nbsp;&nbsp; Segmentation by Targeted Ligands: &nbsp;&nbsp;&nbsp; by Peptides &nbsp;&nbsp;&nbsp; Small Molecules &nbsp;&nbsp;&nbsp; Antibodies &nbsp;&nbsp;&nbsp; Others &nbsp;&nbsp;&nbsp; Segmentation by Radionuclides: &nbsp;&nbsp;&nbsp; ?-emitters &nbsp;&nbsp;&nbsp; -emitters &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Prostate Cancer &nbsp;&nbsp;&nbsp; Liver Cancer &nbsp;&nbsp;&nbsp; Breast Cancer &nbsp;&nbsp;&nbsp; Lung Cancer &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Bayer &nbsp;&nbsp;&nbsp; Progenics (Lantheus) &nbsp;&nbsp;&nbsp; Acrotech Biopharma Inc &nbsp;&nbsp;&nbsp; BMS &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Eli Lilly &nbsp;&nbsp;&nbsp; Convergent Therapeutics &nbsp;&nbsp;&nbsp; Grand Pharmaceutical &nbsp;&nbsp;&nbsp; Bivision Pharmaceuticals &nbsp;&nbsp;&nbsp; Jiangsu Hengrui Key Questions Addressed in this Report What is the 10-year outlook for the global Radioligand Therapy Drugs for Cancer market? What factors are driving Radioligand Therapy Drugs for Cancer market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Radioligand Therapy Drugs for Cancer market opportunities vary by end market size? How does Radioligand Therapy Drugs for Cancer break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Radioligand Therapy Drugs for Cancer Annual Sales 2021-2032 &nbsp;2.1.2 World Current & Future Analysis for Radioligand Therapy Drugs for Cancer by Geographic Region, 2021, 2025 & 2032 &nbsp;2.1.3 World Current & Future Analysis for Radioligand Therapy Drugs for Cancer by Country/Region, 2021, 2025 & 2032 &nbsp;2.2 Radioligand Therapy Drugs for Cancer Segment by Type &nbsp;2.2.1 Lutetium 177 &nbsp;2.2.2 Radium 223 &nbsp;2.2.3 Acetium 225 &nbsp;2.2.4 Others &nbsp;2.2.5 Radioligand Therapy Drugs for Cancer Sales by Type &nbsp;2.2.5.1 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021-2026) &nbsp;2.2.5.2 Global Radioligand Therapy Drugs for Cancer Revenue and Market Share by Type (2021-2026) &nbsp;2.2.5.3 Global Radioligand Therapy Drugs for Cancer Sale Price by Type (2021-2026) &nbsp;2.3 Radioligand Therapy Drugs for Cancer Segment by Targeted Ligands &nbsp;2.3.1 by Peptides &nbsp;2.3.2 Small Molecules &nbsp;2.3.3 Antibodies &nbsp;2.3.4 Others &nbsp;2.3.5 Radioligand Therapy Drugs for Cancer Sales by Targeted Ligands &nbsp;2.3.5.1 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Targeted Ligands (2021-2026) &nbsp;2.3.5.2 Global Radioligand Therapy Drugs for Cancer Revenue and Market Share by Targeted Ligands (2021-2026) &nbsp;2.3.5.3 Global Radioligand Therapy Drugs for Cancer Sale Price by Targeted Ligands (2021-2026) &nbsp;2.4 Radioligand Therapy Drugs for Cancer Segment by Radionuclides &nbsp;2.4.1 ?-emitters &nbsp;2.4.2 ï¿½-emitters &nbsp;2.4.3 Others &nbsp;2.4.4 Radioligand Therapy Drugs for Cancer Sales by Radionuclides &nbsp;2.4.4.1 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Radionuclides (2021-2026) &nbsp;2.4.4.2 Global Radioligand Therapy Drugs for Cancer Revenue and Market Share by Radionuclides (2021-2026) &nbsp;2.4.4.3 Global Radioligand Therapy Drugs for Cancer Sale Price by Radionuclides (2021-2026) &nbsp;2.5 Radioligand Therapy Drugs for Cancer Segment by Application &nbsp;2.5.1 Prostate Cancer &nbsp;2.5.2 Liver Cancer &nbsp;2.5.3 Breast Cancer &nbsp;2.5.4 Lung Cancer &nbsp;2.5.5 Others &nbsp;2.5.6 Radioligand Therapy Drugs for Cancer Sales by Application &nbsp;2.5.6.1 Global Radioligand Therapy Drugs for Cancer Sale Market Share by Application (2021-2026) &nbsp;2.5.6.2 Global Radioligand Therapy Drugs for Cancer Revenue and Market Share by Application (2021-2026) &nbsp;2.5.6.3 Global Radioligand Therapy Drugs for Cancer Sale Price by Application (2021-2026) 3 Global by Company &nbsp;3.1 Global Radioligand Therapy Drugs for Cancer Breakdown Data by Company &nbsp;3.1.1 Global Radioligand Therapy Drugs for Cancer Annual Sales by Company (2021-2026) &nbsp;3.1.2 Global Radioligand Therapy Drugs for Cancer Sales Market Share by Company (2021-2026) &nbsp;3.2 Global Radioligand Therapy Drugs for Cancer Annual Revenue by Company (2021-2026) &nbsp;3.2.1 Global Radioligand Therapy Drugs for Cancer Revenue by Company (2021-2026) &nbsp;3.2.2 Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Company (2021-2026) &nbsp;3.3 Global Radioligand Therapy Drugs for Cancer Sale Price by Company &nbsp;3.4 Key Manufacturers Radioligand Therapy Drugs for Cancer Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Radioligand Therapy Drugs for Cancer Product Location Distribution &nbsp;3.4.2 Players Radioligand Therapy Drugs for Cancer Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Radioligand Therapy Drugs for Cancer by Geographic Region &nbsp;4.1 World Historic Radioligand Therapy Drugs for Cancer Market Size by Geographic Region (2021-2026) &nbsp;4.1.1 Global Radioligand Therapy Drugs for Cancer Annual Sales by Geographic Region (2021-2026) &nbsp;4.1.2 Global Radioligand Therapy Drugs for Cancer Annual Revenue by Geographic Region (2021-2026) &nbsp;4.2 World Historic Radioligand Therapy Drugs for Cancer Market Size by Country/Region (2021-2026) &nbsp;4.2.1 Global Radioligand Therapy Drugs for Cancer Annual Sales by Country/Region (2021-2026) &nbsp;4.2.2 Global Radioligand Therapy Drugs for Cancer Annual Revenue by Country/Region (2021-2026) &nbsp;4.3 Americas Radioligand Therapy Drugs for Cancer Sales Growth &nbsp;4.4 APAC Radioligand Therapy Drugs for Cancer Sales Growth &nbsp;4.5 Europe Radioligand Therapy Drugs for Cancer Sales Growth &nbsp;4.6 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Growth 5 Americas &nbsp;5.1 Americas Radioligand Therapy Drugs for Cancer Sales by Country &nbsp;5.1.1 Americas Radioligand Therapy Drugs for Cancer Sales by Country (2021-2026) &nbsp;5.1.2 Americas Radioligand Therapy Drugs for Cancer Revenue by Country (2021-2026) &nbsp;5.2 Americas Radioligand Therapy Drugs for Cancer Sales by Type (2021-2026) &nbsp;5.3 Americas Radioligand Therapy Drugs for Cancer Sales by Application (2021-2026) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Radioligand Therapy Drugs for Cancer Sales by Region &nbsp;6.1.1 APAC Radioligand Therapy Drugs for Cancer Sales by Region (2021-2026) &nbsp;6.1.2 APAC Radioligand Therapy Drugs for Cancer Revenue by Region (2021-2026) &nbsp;6.2 APAC Radioligand Therapy Drugs for Cancer Sales by Type (2021-2026) &nbsp;6.3 APAC Radioligand Therapy Drugs for Cancer Sales by Application (2021-2026) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Radioligand Therapy Drugs for Cancer by Country &nbsp;7.1.1 Europe Radioligand Therapy Drugs for Cancer Sales by Country (2021-2026) &nbsp;7.1.2 Europe Radioligand Therapy Drugs for Cancer Revenue by Country (2021-2026) &nbsp;7.2 Europe Radioligand Therapy Drugs for Cancer Sales by Type (2021-2026) &nbsp;7.3 Europe Radioligand Therapy Drugs for Cancer Sales by Application (2021-2026) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Radioligand Therapy Drugs for Cancer by Country &nbsp;8.1.1 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales by Country (2021-2026) &nbsp;8.1.2 Middle East & Africa Radioligand Therapy Drugs for Cancer Revenue by Country (2021-2026) &nbsp;8.2 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales by Type (2021-2026) &nbsp;8.3 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales by Application (2021-2026) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs for Cancer &nbsp;10.3 Manufacturing Process Analysis of Radioligand Therapy Drugs for Cancer &nbsp;10.4 Industry Chain Structure of Radioligand Therapy Drugs for Cancer 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Radioligand Therapy Drugs for Cancer Distributors &nbsp;11.3 Radioligand Therapy Drugs for Cancer Customer 12 World Forecast Review for Radioligand Therapy Drugs for Cancer by Geographic Region &nbsp;12.1 Global Radioligand Therapy Drugs for Cancer Market Size Forecast by Region &nbsp;12.1.1 Global Radioligand Therapy Drugs for Cancer Forecast by Region (2027-2032) &nbsp;12.1.2 Global Radioligand Therapy Drugs for Cancer Annual Revenue Forecast by Region (2027-2032) &nbsp;12.2 Americas Forecast by Country (2027-2032) &nbsp;12.3 APAC Forecast by Region (2027-2032) &nbsp;12.4 Europe Forecast by Country (2027-2032) &nbsp;12.5 Middle East & Africa Forecast by Country (2027-2032) &nbsp;12.6 Global Radioligand Therapy Drugs for Cancer Forecast by Type (2027-2032) &nbsp;12.7 Global Radioligand Therapy Drugs for Cancer Forecast by Application (2027-2032) 13 Key Players Analysis &nbsp;13.1 Novartis &nbsp;13.1.1 Novartis Company Information &nbsp;13.1.2 Novartis Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.1.3 Novartis Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.1.4 Novartis Main Business Overview &nbsp;13.1.5 Novartis Latest Developments &nbsp;13.2 Bayer &nbsp;13.2.1 Bayer Company Information &nbsp;13.2.2 Bayer Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.2.3 Bayer Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.2.4 Bayer Main Business Overview &nbsp;13.2.5 Bayer Latest Developments &nbsp;13.3 Progenics (Lantheus) &nbsp;13.3.1 Progenics (Lantheus) Company Information &nbsp;13.3.2 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.3.3 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.3.4 Progenics (Lantheus) Main Business Overview &nbsp;13.3.5 Progenics (Lantheus) Latest Developments &nbsp;13.4 Acrotech Biopharma Inc &nbsp;13.4.1 Acrotech Biopharma Inc Company Information &nbsp;13.4.2 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.4.4 Acrotech Biopharma Inc Main Business Overview &nbsp;13.4.5 Acrotech Biopharma Inc Latest Developments &nbsp;13.5 BMS &nbsp;13.5.1 BMS Company Information &nbsp;13.5.2 BMS Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.5.3 BMS Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.5.4 BMS Main Business Overview &nbsp;13.5.5 BMS Latest Developments &nbsp;13.6 AstraZeneca &nbsp;13.6.1 AstraZeneca Company Information &nbsp;13.6.2 AstraZeneca Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.6.3 AstraZeneca Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.6.4 AstraZeneca Main Business Overview &nbsp;13.6.5 AstraZeneca Latest Developments &nbsp;13.7 Eli Lilly &nbsp;13.7.1 Eli Lilly Company Information &nbsp;13.7.2 Eli Lilly Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.7.3 Eli Lilly Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.7.4 Eli Lilly Main Business Overview &nbsp;13.7.5 Eli Lilly Latest Developments &nbsp;13.8 Convergent Therapeutics &nbsp;13.8.1 Convergent Therapeutics Company Information &nbsp;13.8.2 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.8.3 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.8.4 Convergent Therapeutics Main Business Overview &nbsp;13.8.5 Convergent Therapeutics Latest Developments &nbsp;13.9 Grand Pharmaceutical &nbsp;13.9.1 Grand Pharmaceutical Company Information &nbsp;13.9.2 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.9.3 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.9.4 Grand Pharmaceutical Main Business Overview &nbsp;13.9.5 Grand Pharmaceutical Latest Developments &nbsp;13.10 Bivision Pharmaceuticals &nbsp;13.10.1 Bivision Pharmaceuticals Company Information &nbsp;13.10.2 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.10.4 Bivision Pharmaceuticals Main Business Overview &nbsp;13.10.5 Bivision Pharmaceuticals Latest Developments &nbsp;13.11 Jiangsu Hengrui &nbsp;13.11.1 Jiangsu Hengrui Company Information &nbsp;13.11.2 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product Portfolios and Specifications &nbsp;13.11.3 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.11.4 Jiangsu Hengrui Main Business Overview &nbsp;13.11.5 Jiangsu Hengrui Latest Developments 14 Research Findings and Conclusion

Report	Global Radioligand Therapy Drugs for Cancer Market Size, Share and Analysis Report 2026-2032
Selected License	Multi ID: ILR5239

Buyer Information

Order Summary